Price target
92.570.000.00%
The 21 analysts offering 1 year price forecasts for RARE have a max estimate of — and a min estimate of —.
Analyst rating
Based on 21 analysts giving stock ratings to RARE in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
RARE EPS for the last quarter is −1.40 USD despite the estimation of −1.48 USD. In the next quarter EPS is expected to reach −1.35 USD. Track more of Ultragenyx Pharmaceutical Inc. financials and stay on top of what is up with the company.
In the next quarter Ultragenyx Pharmaceutical Inc. revenue is expected to reach 146.62 M USD. Check out Ultragenyx Pharmaceutical Inc. revenue and earnings and make informed decisions.
According to analysts, RARE price target is 92.57 USD with a max estimate of 140.00 USD and a min estimate of 48.00 USD. Check if this forecast comes true in a year, meanwhile watch Ultragenyx Pharmaceutical Inc. stock price chart and keep track of the current situation with RARE news and stock market news.
We've gathered opinions of 21 analysts rating RARE stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.